What's breaking now, across thousands of outlets.
EnGene’s latest data on its bladder cancer therapy looked better than an earlier cut in May, which had gutted the biotech’s stock after it reported underwhelming durability results. But it still remains ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
The World Bank has urged Nigerian state governments to sustain gains recorded in child survival, malaria prevention, and immunisation under the IMPACT proj Read More…
One blood marker could show if a patient has serous tubal intraepithelial carcinoma, an early sign of advanced ovarian cancer.
Plus, news about Vor Bio, RemeGen, Merck KGaA, Aidea, Astellas and Immuneering. BioNTech acquires PRV for $205 million: The German biotech scooped up the FDA voucher from Scholar Rock, with plans ...
Jaylen Watson underwent successful shoulder surgery after trying "every single possible" thing to keep playing through the injury.
Pfizer spent up to $10 billion to buy Metsera last year. Now, it’s bringing in private equity behemoth Blackstone to help pay for the deal.
A Swiss woman who tested positive for the Ebola virus in Nigeria has recovered and been discharged from a hospital in Geneva after being evacuated for trea Read More…
